Jefferies reaffirmed its positive stance on Praxis Precision Medicines Inc . (NASDAQ:PRAX), maintaining a Buy rating and a price target of $305.00. The stock, currently valued at $1.54 billion market ...
ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary novel ...
Lorraine Kelly has opened up about her struggles with confidence and admits she feels 'working class cringe' despite being on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback